Provided by Tiger Trade Technology Pte. Ltd.

Merck

119.45
+0.07500.06%
Volume:2.16M
Turnover:258.69M
Market Cap:296.47B
PE:16.41
High:120.06
Open:119.50
Low:118.66
Close:119.37
52wk High:125.14
52wk Low:73.31
Shares:2.48B
Float Shares:2.48B
Volume Ratio:0.32
T/O Rate:0.09%
Dividend:3.24
Dividend Rate:2.71%
EPS(TTM):7.28
EPS(LYR):7.28
ROE:36.88%
ROA:12.04%
PB:5.64
PE(LYR):16.41

Loading ...

Merck and Mayo Clinic Form AI-Driven Drug Discovery Collaboration

Reuters
·
Feb 18

EXCLUSIVE-California preparing lawsuit over Trump administration vaccine changes

Reuters
·
Feb 18

Top News Today/Canada: Inflation Cooled a Bit in January

Dow Jones
·
Feb 18

Merck announces Health Canada approval of KEYTRUDA SC

TIPRANKS
·
Feb 18

BRIEF-Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell

Reuters
·
Feb 18

Health Canada Approves Merck's Subcutaneous KEYTRUDA for Multiple Cancers

Reuters
·
Feb 18

Health Canada Approves Keytruda Sc™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

THOMSON REUTERS
·
Feb 18

Is Merck’s First PD-1 Ovarian Cancer Approval Reshaping The Investment Case For Merck (MRK)?

Simply Wall St.
·
Feb 17

REFILE-Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees

Reuters
·
Feb 16

A Look At Merck (MRK) Valuation After New Keytruda Approval And Oncology Data Updates

Simply Wall St.
·
Feb 15

ECOB, Delta, Merck, Carnival, RTX Insiders Cash Out

TIPRANKS
·
Feb 14

Merck Shares Rise After Deutsche Bank Upgrade

MT Newswires Live
·
Feb 14

Merck upgraded to Buy from Hold at Deutsche Bank

TIPRANKS
·
Feb 13

Merck Shares up 1.9% Premarket After Deutsche Bank Raises to Buy From Hold

THOMSON REUTERS
·
Feb 13

Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115

MT Newswires Live
·
Feb 13

Merck’s New Ovarian Cancer Win And Women’s Health Push Tested By Valuation

Simply Wall St.
·
Feb 13

Merck Chief Marketing Officer Chirfi Guindo Reports Disposal of Common Shares

Reuters
·
Feb 13

Merck Unveils New Data on Bladder and Kidney Cancer Treatments at 2026 ASCO GU Symposium

Reuters
·
Feb 12

Merck Advances Treatment of Bladder and Kidney Cancers With New Data at 2026 Asco Gu Cancers Symposium

THOMSON REUTERS
·
Feb 12

Sanofi Abruptly Replaces CEO Amid R&D Setbacks, Merck Executive Takes Helm

Stock News
·
Feb 12